Insight Molecular Diagnostics Inc. Income (Loss) from Continuing Operations, Per Basic Share
Insight Molecular Diagnostics Inc. (IMDX) reported Income (Loss) from Continuing Operations, Per Basic Share of -$4.66 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2025-03-24
- Insight Molecular Diagnostics Inc. income (loss) from continuing operations, per basic share for the quarter ending 2024-09-30 was -$0.98.
- Insight Molecular Diagnostics Inc. income (loss) from continuing operations, per basic share for the quarter ending 2024-06-30 was -$0.36.
- Insight Molecular Diagnostics Inc. income (loss) from continuing operations, per basic share for the quarter ending 2024-03-31 was -$1.13, a 237.80% decline year-over-year.
- Insight Molecular Diagnostics Inc. income (loss) from continuing operations, per basic share for the quarter ending 2023-09-30 was -$0.81.
- Insight Molecular Diagnostics Inc. income (loss) from continuing operations, per basic share for fiscal 2024 was -$4.66.
- Insight Molecular Diagnostics Inc. income (loss) from continuing operations, per basic share for fiscal 2023 was -$3.37.
- Insight Molecular Diagnostics Inc. income (loss) from continuing operations, per basic share for fiscal 2022 was -$3.45.
- Insight Molecular Diagnostics Inc. income (loss) from continuing operations, per basic share for fiscal 2021 was -$0.49.
| Period end | Income (Loss) from Continuing Operations, Per Basic Share 3 month | Income (Loss) from Continuing Operations, Per Basic Share 3 month as first filed | Income (Loss) from Continuing Operations, Per Basic Share 6 month | Income (Loss) from Continuing Operations, Per Basic Share 6 month as first filed | Income (Loss) from Continuing Operations, Per Basic Share 9 month | Income (Loss) from Continuing Operations, Per Basic Share 9 month as first filed | Income (Loss) from Continuing Operations, Per Basic Share 12 month | Income (Loss) from Continuing Operations, Per Basic Share 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | -$4.66 10-K · filed 2025-03-24 | |||||||
| 2024-09-30 | -$0.98 10-Q · filed 2024-11-12 | -$2.36 10-Q · filed 2024-11-12 | ||||||
| 2024-06-30 | -$0.36 10-Q · filed 2024-08-08 | -$1.32 10-Q · filed 2024-08-08 | ||||||
| 2024-03-31 | -$1.13 10-Q · filed 2024-05-15 | |||||||
| 2023-12-31 | -$3.37 10-K · filed 2025-03-24 | |||||||
| 2023-09-30 | -$0.81 10-Q · filed 2024-11-12 | -$0.79 10-Q · filed 2023-11-09 | -$1.29 10-Q · filed 2024-11-12 | -$1.19 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | -$1.07 10-Q · filed 2024-08-08 | -$1.03 10-Q · filed 2023-08-10 | -$0.41 10-Q · filed 2024-08-08 | -$0.34 10-Q · filed 2023-08-10 | ||||
| 2023-03-31 | $0.82 10-Q · filed 2024-05-15 | $0.04 10-Q · filed 2023-05-15 | ||||||
| 2022-12-31 | -$3.45 10-K · filed 2024-04-16 | -$0.17 10-K · filed 2023-04-12 | ||||||
| 2022-09-30 | -$0.31 10-Q · filed 2023-11-09 | -$1.22 10-Q · filed 2023-11-09 | ||||||
| 2022-06-30 | -$0.24 10-Q · filed 2023-08-10 | -$0.93 10-Q · filed 2023-08-10 | ||||||
| 2022-03-31 | -$0.04 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | -$0.49 10-K · filed 2023-04-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |